NCIC CLINICAL TRIALS GROUP

LUNG

DISEASE SITE COMMITTEE MEETING

AGENDA

ROOM: CHURCHILL A

DELTA CHELSEA, TORONTO, ON

SATURDAY, MAY 2ND, 2009

CHAIRS: DR. G. GOSS & DR. Y. UNG

(8:30 A.M. – 4:15 P.M.)

8:30 A.M. WELCOME AND ANNOUNCEMENTS

Dr. G. Goss

9:00 A.M. UPDATE ON NCI INTEGRATED THORACIC MALIGNANCIES STEERING COMMITTEE

9:05 A.M. SUBCOMMITTEE REPORTS

- SMALL CELL Dr. P. Ellis
- RADIATION Dr. Y. Ung
- MESOTHELIOMA AND THYMOMA Dr. C. Lee
- CORRELATIVE SCIENCES Dr. M. Tsao

9:45 A.M. COFFEE BREAK (~ 20 MINUTES)

10:05 A.M. NON-SMALL CELL LUNG CANCER

SURGICAL ADJUVANT AND NEOADJUVANT AND LOCALLY ADVANCED TRIALS

BR.16: RANDOMIZED PLACEBO CONTROLLED TRIAL OF ADJUVANT SELENIUM IN COMPLETELY RESECTED STAGE I NSCLC (ECOG) Dr. T. Waddell

BR.19: RANDOMIZED TRIAL OF ADJUVANT GEFITINIB VERSUS PLACEBO AFTER COMPLETE RESECTION OF STAGE IB, II IIIA NSCLC Dr. G. Goss

BRC.2: (ECOG 1505) RANDOMIZED TRIAL OF CHEMOTHERAPY +/- BEVACIZUMAB IN COMPLETELY RESECTED STAGE IB-IIIA NSCLC Dr. C. Butts

BRC.2: (ECOG 1505) RANDOMIZED TRIAL OF CHEMOTHERAPY +/- BEVACIZUMAB IN COMPLETELY RESECTED STAGE IB-IIIA NSCLC Economic Analysis Dr. N. Leighl

BRC.5: (CALGB 140503) A PHASE III RANDOMIZED TRIAL OF LOBECTOMY VERSUS SUB-LOBAR RESECTION FOR SMALL (< 2 CM) PERIPHERAL NSCLC Dr. M. De Perrot

BR.27: (LUNG-ART) POST-OPERATIVE ADJUVANT RADIATION FOR COMPLETELY RESECTED N2 NSCLC Dr. Y Ung

CONTINUED …
11:05 A.M. **ADVANCED NSCLC**

BR.24: **RANDOMIZED TRIAL OF PACLITAXEL AND CARBOPLATIN +/- AZD 2171 IN ADVANCED NON-SCLC**

Dr. G. Goss

BRC.4: **(N0723) A PHASE III BIOMARKER VALIDATION STUDY OF SECOND-LINE THERAPY IN PATIENTS WITH ADVANCED NSCLC RANDOMIZED TO PEMETREXED VERSUS ERLOTINIB**

Dr. G. Liu

BR.29: **A DOUBLE BLIND RANDOMIZED TRIAL OF CEDIRANIB VERUS PLACEBO IN PATIENTS RECEIVING PACLITAXEL/CARBOPLATIN CHEMOTHERAPY FOR THE TREATMENT OF ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER**

Dr. S. Laurie

11:30 A.M. **RADIOTHERAPY STUDIES**

BR.25: **HYPOFRACTIONATED RADIOTHERAPY FOR MEDICALLY INOPERABLE NSCLC**

Dr. P. Cheung

BRC.4: **PCI IN NSCLC**

Dr. A. Sun

RTOG 0212: **PCI IN SCLC**

Dr. A. Sun

11:50 P.M. **SMALL CELL LUNG CANCER**

BR.28: **(CONVERT) ONCE DAILY VERSUS TWICE DAILY RADIATION FOR LIMITED SCLC**

Dr. A. Bezjak

12:00 P.M. **LUNCH (90 MINUTES)**

1:30 P.M. **IND STUDIES**

IND.183: **PHASE II TRIAL OF SUTENT IN 2ND-LINE TREATMENT OF MALIGNANT MESOTHELIOMA**

Dr. S. Laurie

IND.190: **PHASE I-II TRIAL OF ETOPOSIDE / CISPLATIN + IGFR1 INHIBITOR IN EXTENSIVE STAGE SCLC**

Dr. P. Ellis

IND 196: **PHASE I/II C-MET INHIBITOR/ERLOTINIB**

Dr. N. Leighl / Dr. C. Ho

REPORT FROM THE IND COMMITTEE

Dr. G. Goss

2:30 P.M. **COFFEE BREAK (~ 15 MIN)**

2:45 P.M. **ECONOMIC AND DATA-BASE ANALYSES OF LUNG TRIALS**

- Economic Analyses - Active and Planned
  
  Dr. N. Leighl

- Database Analyses
  
  Dr. F. Shepherd

3:30 P.M. **NEW STUDIES**

- BR.26
  
  Dr. P. Ellis

- Other
  
  Dr. G. Goss

4:00 P.M. **CONCLUSIONS**